Human Breast Cell MDA-MB-231-based Proliferation Assay Service
Creative Biolabs specializes in providing a proliferation assay using human breast cancer cells MDA-MB-231. This cell line is commonly used in research and drug development for breast cancer treatments. Our assay can measure the growth rate of these MDA-MB-231 cells, allowing for the evaluation of the effects of various compounds or treatments on cell proliferation. Our team of experts can conduct the assay in a timely and accurate manner, providing valuable data for further research and development in the field of breast cancer.
MDA-MB-231 Cell Line
MDA-MB-231 is a human breast cancer cell line that was derived from a metastatic site in the pleural effusion of a 51-year-old female patient with adenocarcinoma of the breast. These cells are triple-negative, meaning they do not express estrogen receptor (ER), progesterone receptor (PR), or human epidermal growth factor receptor 2 (HER2). The MDA-MB-231 cell line is widely used in cancer research as a model for studying aggressive, metastatic breast cancer. These cells are highly invasive and have the ability to form tumors in animal models, making them valuable for studying tumor progression and metastasis. Researchers use MDA-MB-231 cells to investigate potential therapeutic targets and to test the efficacy of anti-cancer drugs.
MDA-MB-231-based Proliferation Assay at Creative Biolabs
Our MDA-MB-231-based Tumor Cell Proliferation Assay offers a reliable and efficient way to assess the growth and proliferation of MDA-MB-231 breast cancer cells. The assay utilizes a luminescent substrate that emits light in response to the metabolic activity of the cells, allowing for sensitive and quantitative measurement of cell proliferation. Our experienced team of scientists can perform the assay in a timely manner, providing you with accurate data on the growth kinetics of MDA-MB-231 cells in response to various treatments or conditions. This information can be valuable for evaluating the efficacy of anti-cancer drugs, screening for potential therapeutic agents, or studying the mechanisms underlying tumor progression.
Assay Information
Assay Procedure
Applications of Our Assay
The MDA-MB-231 cell line is commonly used in drug screening assays to test the efficacy of potential anti-cancer drugs.
By utilizing the MDA-MB-231 proliferation assay, researchers can identify potential therapeutic targets for breast cancer treatment.
The proliferation assay can also be used to study the mechanisms underlying cancer progression and drug resistance in MDA-MB-231 cells.
The MDA-MB-231 proliferation assay can be used to identify novel biomarkers associated with breast cancer progression or drug response.
The MDA-MB-231 proliferation assay can potentially be used in the development of personalized treatment strategies for breast cancer research.
Frequently Asked Question
Q1: Why use MDA-MB-231 cells for the proliferation assay?
A1: MDA-MB-231 cells are a commonly used triple-negative breast cancer cell line that has a high proliferation rate. This characteristic makes them well-suited for studying cellular proliferation in response to various treatments or conditions. Additionally, they are easy to culture and maintain in the laboratory, making them a practical choice for conducting proliferation assays. Furthermore, because MDA-MB-231 cells are widely used in breast cancer research, results obtained using these cells can be easily compared and validated with other studies in the field.
Contact Us
For more information about our MDA-MB-231-based proliferation assay service, please contact us now. Our team of experienced scientists is dedicated to providing high-quality data and personalized support to meet your research needs.
For Research Use Only | Not For Clinical Use
Download our brochure
